

INDOCO REMEDIES LIMITED

Regd. Office : Indoco House, 166, CST Road, Santacruz (E), Mumbai 400 098

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 31ST MARCH 2011

(Rs. In Lacs)

Sr. No.	Particulars	Quarter ended 31.03.2011 (Unaudited)	Quarter ended 31.03.2010 (Unaudited)	Year ended 31.03.2011 (Unaudited)	Year ended 31.03.2010 (Audited)
1	(a) Sales and Income from Operations	12,171	11,003	48,356	40,231
	Less : Excise Duty	127	116	509	402
	Net Sales and Income from Operations	12,044	10,887	47,847	39,829
	(b) Other Operating income	240	145	789	431
	Total	12,284	11,032	48,636	40,260
2	Expenditure :				
	(a) (Increase)/Decrease in Finished Goods Stock in trade and work in progress	452	(374)	(1,184)	(593)
	(b) Consumption of raw materials	4,343	4,791	19,345	15,404
	(c) Purchase of traded goods	527	732	3,153	2,521
	(d) Employees cost	1,753	1,487	6,702	5,646
	(e) Depreciation	349	338	1,347	1,210
	(f) Research & Development Expenses	268	297	933	1,022
	(g) Other Expenditure	3,145	2,838	12,452	10,462
	(h) Total	10,837	10,109	42,748	35,672
3	Profit from Operations before Other Income, Interest and Exceptional Items	1,447	923	5,888	4,588
4	Other Income	2	1	5	16
5	Profit before Interest and Exceptional Items	1,449	924	5,893	4,604
6	Interest	63	72	240	291
7	Profit after Interest but before Exceptional Items	1,386	852	5,653	4,313
8	Exceptional Items	-	-	-	-
9	Profit from Ordinary Activities before tax	1,386	852	5,653	4,313
10	Tax Expenses - Current	276	145	1,127	731
	- Deferred	30	51	148	126
	- Prior Year	-	(22)	-	(22)
	- MAT Credit	(136)	(145)	(727)	(731)
11	Net Profit from Ordinary Activities after tax	1,216	823	5,105	4,209
12	Extraordinary Items	-	-	-	-
13	Net Profit for the period	1,216	823	5,105	4,209
14	Paid up Equity Share Capital (Face value Rs.10/- each)	1,228.67	1228.67	1228.67	1,228.67
15	Reserves excluding Revaluation Reserves	-	-	-	29,822
16	Earning Per Share (EPS) - Not Annualised - Rs.				
	(a) Basic and diluted EPS before Extraordinary Items	9.90	6.70	41.55	34.26
	(b) Basic and diluted EPS after Extraordinary Items	9.90	6.70	41.55	34.26
17	Public shareholding				
	- No of Shares	47,95,103	48,57,636	47,95,103	48,57,636
	- % of Shareholding	39.03	39.53	39.03	39.53
18	Promoters and promoters group shareholding				
	a) Pledged/Encumbered				
	- Number of shares	8,200	8,200	8,200	8,200
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	0.11	0.11	0.11	0.11
	- Percentage of shares (as a % of the total share capital of the company)	0.07	0.07	0.07	0.07
	b) Non-encumbered				
	- Number of shares	74,83,411	74,20,878	74,83,411	74,20,878
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	99.89	99.89	99.89	99.89
	- Percentage of shares (as a % of the total share capital of the company)	60.90	60.40	60.90	60.40

Notes :

- The company has only one primary reportable segment of activity, namely, Pharmaceuticals.
- The figures for the previous periods have been regrouped and reclassified, wherever necessary.
- Summary of investor complaints : As on 01.01.2011: Nil, Received during quarter: 3, Resolved: 3, Pending as on 31.03.2011: Nil.
- The above results have been recommended by the Audit Committee and taken on record at the meeting of Board of Directors held on 27th April 2011 and have been subjected to a Limited Review by the Statutory Auditors of the Company.

By Order of the Board

Place : Mumbai
Date : April 27, 2011

Suresh G. Kare
Chairman & Managing Director